[Effects of Fuzheng Yiliu Granule on expression of CD44v6 and nm23-H1 in esophageal carcinoma treated with radiotherapy].
OBJECTIVE
To evaluate the effects of Fuzheng Yiliu Granule on the expression of CD44v6 and nm23-H1 in esophageal carcinoma treated with radiotherapy.


METHODS
Sixty-three cases of esophageal carcinoma were randomly divided into two groups: Fuzheng Yiliu Granule plus radiotherapy treated group (n=30) and radiotherapy treated group (n=33). The carcinoma specimens were obtained through endoscopic biopsy before and after twenty-one days of treatment. The expression of CD44v6 and nm23-H1 was determined in the sixty-three specimens of esophageal carcinoma by immunohistochemical SABC methods.


RESULTS
After twenty-one days of treatment, the positive rates of CD44v6 in the Fuzheng Yiliu Granule plus radiotherapy treated group and the radiotherapy treated group were 40.0% and 69.7%, respectively, and there was significant difference between the two groups (P<0.05). The positive rates of nm23-H1 in the Fuzheng Yiliu Granule plus radiotherapy treated group and the radiotherapy treated group were 20.0% and 21.2%, respectively, and the difference was not significant between the two groups (P>0.05).


CONCLUSIONS
Fuzheng Yiliu Granule can lower the expression of CD44v6 in esophageal carcinoma, and may prevent infiltration and lymph node metastasis of esophageal carcinoma.
Zhao
Jian-Xiong
JX
Institute of Integrated Traditional Chinese and Western Medicine, Lanzhou Medical College, Lanzhou, Gansu Province 730000, China. zhaojianxiong@mail.lazmc.edu.cn
Li
Xue-Feng
XF
D000368:Aged; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*; D004947:Esophagus / Q000737:chemistry / Q000187:drug effects / Q000528:radiation effects; D006023:Glycoproteins / Q000096:biosynthesis*; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D007150:Immunohistochemistry; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D054778:NM23 Nucleoside Diphosphate Kinases; D009701:Nucleoside-Diphosphate Kinase / Q000096:biosynthesis*; D016896:Treatment Outcome
C112697:CD44v6 antigen; D004365:Drugs, Chinese Herbal; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D054778:NM23 Nucleoside Diphosphate Kinases; C517938:NME1 protein, human; D009701:Nucleoside-Diphosphate Kinase